Nyxoah SA
Research Nyxoah SA (NYXH) on Bullrun: market cap USD 164.12M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerNYXH
- ExchangeNASDAQ
- CountryBelgium
- SectorHealthcare
- IndustryMedical Instruments & Supplies
- CurrencyUSD
- Market capUSD 164.12M
- Financial periodQ2 2026
- RevenueEUR 7.68M
- Net income-EUR 32.96M
- Free cash flow-EUR 17.86M
- Gross margin59.7%
Valuation Snapshot
latest market cap is USD 164.12M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 10.02M | -EUR 90.08M | -EUR 72.75M | 63.1% | -2.37 | EUR 30.00M | EUR 40.48M | EUR 49.13M |
| FY2024 | EUR 4.52M | -EUR 59.24M | -EUR 55.30M | 65.6% | -1.81 | EUR 34.19M | EUR 22.65M | EUR 113.25M |
| FY2023 | EUR 4.35M | -EUR 43.21M | -EUR 47.28M | 61.9% | -1.55 | EUR 21.61M | EUR 12.70M | EUR 98.02M |
| FY2022 | EUR 3.08M | -EUR 31.23M | -EUR 29.64M | 62.7% | -1.21 | EUR 17.89M | EUR 12.24M | EUR 120.32M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 164.12M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 197.92M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 299.42M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 133.05M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 128.97M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 592.77M | n/a | n/a | n/a |
About Nyxoah SA
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea. Its lead solution is the Genio system, a hypoglossal neurostimulations therapy for obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Nyxoah SA's market cap?
Nyxoah SA's market capitalization is USD 164.12M.
What does Nyxoah SA do?
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea. Its lead solution is the Genio system, a hypoglossal neurostimulations therapy for obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.